Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study

International Journal of Cancer

Volumn 138, Issue 10, 2016, Pages 2428-2438

  Rachel Skinner, S ^a,v   Wheeler, Cosette M ^b   Romanowski, Barbara ^c   Castellsagué, Xavier ^d   Lazcano Ponce, Eduardo ^e   Rowena Del Rosario Raymundo, M ^f   Vallejos, Carlos ^g   Minkina, Galina ^h   Pereira Da Silva, Daniel ⁱ   McNeil, Shelly ^j   Prilepskaya, Vera ^k   Gogotadze, Irina ^l   Money, Deborah ^m   Garland, Suzanne M ⁿ   Romanenko, Viktor ^o   Harper, Diane M ^p   Levin, Myron J ^q   Chatterjee, Archana ^r   Geeraerts, Brecht ^s   Struyf, Frank ^s   Dubin, Gary ^t   Bozonnat, Marie Cécile ^u   Rosillon, Dominique ^s   Baril, Laurence ^s   more..

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f San Pablo Colleges Medical Center   (Philippines)

^g National Cancer Institute INEN and Oncosalud   (Peru)

^h Clinical Oncology Hospital Moscow   (Russian Federation)

ⁱ Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^j DALHOUSIE UNIVERSITY   (Canada)

^k RESEARCH CENTER OF OBSTETRICS   (Russian Federation)

^l City Sport Medical Center   (Russian Federation)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

^o City Children's Hospital N40   (Russian Federation)

^p DARTMOUTH MEDICAL SCHOOL   (United States)

^q Nutrition Obesity Research Center at the University of Colorado   (United States)

^r UNIVERSITY OF SOUTH DAKOTA   (United States)

^s GSK   (Belgium)

^t GLAXOSMITHKLINE   (United States)

^u Children's Hospital Westmead ^*  (France)

^v UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

adult women; CIN; HPV; natural history; VIVIANE

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; TUMOR VIRUS; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; VIRAL CLEARANCE; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; EARLY CANCER DIAGNOSIS; FOLLOW UP; HEALTH SURVEY; IMMUNOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RISK; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

WART VIRUS VACCINE;

ADULT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH SURVEILLANCE; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 84960192786     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29971     Document Type: Article

References (50)

1. Hildesheim A, Schiffman MH, Gravitt PE, et al., Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: 235-40.
2. Koshiol J, Lindsay L, Pimenta JM, et al., Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123-37.
3. de Sanjose S, Quint WG, Alemany L, et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
4. Appleby P, Beral V, Berrington de Gonzalez A, et al., Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 1481-95.
5. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120: 885-91.
6. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 2009; 18: 1060-9.
7. Chaturvedi AK, Madeleine MM, Biggar RJ, et al., Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101: 1120-30.
8. Smith JS, Herrero R, Bosetti C, et al., Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.
9. Smith JS, Munoz N, Herrero R, et al., Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185: 324-31.
10. Dunne EF, Unger ER, Sternberg M, et al., Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-9.
11. Bruni L, Diaz M, Castellsagué X, et al., Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
12. Munoz N, Mendez F, Posso H, et al., Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87.
13. Coupe VM, Berkhof J, Bulkmans NW, et al., Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008; 98: 646-51.
14. Trottier H, Ferreira S, Thomann P, et al., Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70: 8569-77.
15. Moscicki AB, Ma Y, Farhat S, et al., Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16. J Infect Dis 2013; 208: 403-12.
16. Castellsagué X, Naud P, Chow SN, et al., Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 2014; 210: 517-34.
17. Castellsagué X, Paavonen J, Jaisamrarn U, et al., Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infect Dis 2014; 14: 551. doi: 10.1186/s12879-0000-0000-y.
18. Jaisamrarn U, Castellsagué X, Garland SM, et al., Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PloS One 2013; 8: e79260.
19. Skinner SR, Szarewski A, Romanowski B, et al., Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014; 384 (9961): 2213-27. doi: 10.1016/S0140-6736(14)60920-X.
20. van Doorn LJ, Molijn A, Kleter B, et al., Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44: 3292-8.
21. Roset Bahmanyar E, Paavonen J, Naud P, et al., Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 2012; 127: 440-50.
22. Paavonen J, Jenkins D, Bosch FX, et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
23. Lin DYWL., The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074-8.
24. Zeger SL, Liang KY., Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.
25. Insinga RP, Perez G, Wheeler CM, et al., Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20: 287-96.
26. Bulkmans NW, Bleeker MC, Berkhof J, et al., Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005; 117: 177-81.
27. Wheeler CM, Hunt WC, Joste NE, et al., Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475-87.
28. Wentzensen N, Nason M, Schiffman M, et al., No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis 2014; 209: 855-64.
29. Wheeler CM, Hunt WC, Cuzick J, et al., A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 2013; 132: 198-207.
30. Cuzick J, Ho L, Terry G, et al., Individual detection of 14 high risk human papilloma virus genotypes by the Pap type test for the prediction of high grade cervical lesions. J Clin Virol 2014; 60: 44-9.
31. Schiffman M, Herrero R, Desalle R, et al., The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
32. Jit M, Gay N, Soldan K, et al., Estimating progression rates for human papillomavirus infection from epidemiological data. Med Decis Making 2010; 30: 84-98.
33. Tjalma WA, Fiander A, Reich O, et al., Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 2013; 132: 854-67.
34. Rousseau MC, Pereira JS, Prado JC, et al., Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184: 1508-17.
35. Mendez F, Munoz N, Posso H, et al., Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005; 192: 1158-65.
36. Vaccarella S, Franceschi S, Herrero R, et al., Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis 2011; 204: 385-90.
37. Vaccarella S, Franceschi S, Snijders PJ, et al., Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2010; 19: 503-10.
38. Chaturvedi AK, Katki HA, Hildesheim A, et al., Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis 2011; 203: 910-20.
39. Quint W, Jenkins D, Molijn A, et al., One virus, one lesion-individual components of CIN lesions contain a specific HPV type. J Pathol 2012; 227: 62-71.
40. Vaccarella S, Herrero R, Snijders PJ, et al., Smoking and human papillomavirus infection: pooled analysis of the international agency for research on cancer HPV prevalence surveys. Int J Epidemiol 2008; 37: 536-46.
41. Moscicki AB, Hills N, Shiboski S, et al., Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285: 2995-3002.
42. Collins S, Rollason TP, Young LS, et al., Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study. Eur J Cancer 2010; 46: 405-11.
43. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S., Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 1481-95.
44. Szarewski A, Jarvis MJ, Sasieni P, et al., Effect of smoking cessation on cervical lesion size. Lancet 1996; 347: 941-3.
45. Szarewski A, Maddox P, Royston P, et al., The effect of stopping smoking on cervical Langerhans' cells and lymphocytes. BJOG 2001; 108: 295-303.
46. Arbyn M, Roelens J, Simoens C, et al., Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 2013; 3: CD008054.
47. Arbyn M, Ronco G, Anttila A, et al., Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (Suppl 5): F88-F99.
48. Persson M, Elfstrom KM, Brismar Wendel S, et al., Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study. PLoS One 2014; 9: e90023.
49. Schiffman M, Khan MJ, Solomon D, et al., A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 147-50.
50. Munoz N, Manalastas R, Jr., Pitisuttithum P, et al., Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373: 1949-57.